Yarvitan

RSS

Withdrawn

This medicine's authorisation has been withdrawn

mitratapide
MedicineVeterinaryWithdrawn

Lithuanian is available via eTranslation, the European Commission's machine translation service.

Translate to Lithuanian | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for this product has been withdrawn at the request of the marketing authorisation holder.

español (ES) (256.72 KB - PDF)

Rodyti

čeština (CS) (393.52 KB - PDF)

Rodyti

dansk (DA) (256.17 KB - PDF)

Rodyti

Deutsch (DE) (257.38 KB - PDF)

Rodyti

eesti (ET) (255.5 KB - PDF)

Rodyti

ελληνικά (EL) (454.41 KB - PDF)

Rodyti

français (FR) (257.52 KB - PDF)

Rodyti

italiano (IT) (256.43 KB - PDF)

Rodyti

latviešu (LV) (399.71 KB - PDF)

Rodyti

lietuvių (LT) (373.07 KB - PDF)

Rodyti

magyar (HU) (384.35 KB - PDF)

Rodyti

Nederlands (NL) (256.77 KB - PDF)

Rodyti

polski (PL) (403.94 KB - PDF)

Rodyti

português (PT) (257.16 KB - PDF)

Rodyti

slovenčina (SK) (389.05 KB - PDF)

Rodyti

slovenščina (SL) (380.7 KB - PDF)

Rodyti

suomi (FI) (255.8 KB - PDF)

Rodyti

svenska (SV) (256.06 KB - PDF)

Rodyti

Product information

български (BG) (876.69 KB - PDF)

Rodyti

español (ES) (368.06 KB - PDF)

Rodyti

čeština (CS) (682.61 KB - PDF)

Rodyti

dansk (DA) (413.04 KB - PDF)

Rodyti

Deutsch (DE) (363.22 KB - PDF)

Rodyti

eesti (ET) (360.22 KB - PDF)

Rodyti

ελληνικά (EL) (926.55 KB - PDF)

Rodyti

français (FR) (369.55 KB - PDF)

Rodyti

italiano (IT) (358.34 KB - PDF)

Rodyti

latviešu (LV) (723.79 KB - PDF)

Rodyti

lietuvių (LT) (500.34 KB - PDF)

Rodyti

magyar (HU) (667.24 KB - PDF)

Rodyti

Malti (MT) (707.97 KB - PDF)

Rodyti

Nederlands (NL) (359.17 KB - PDF)

Rodyti

polski (PL) (707.86 KB - PDF)

Rodyti

português (PT) (369.01 KB - PDF)

Rodyti

română (RO) (511.36 KB - PDF)

Rodyti

slovenčina (SK) (679.07 KB - PDF)

Rodyti

slovenščina (SL) (667.27 KB - PDF)

Rodyti

suomi (FI) (355.26 KB - PDF)

Rodyti

svenska (SV) (366.58 KB - PDF)

Rodyti
Latest procedure affecting product information:II/0003
20/10/2008

български (BG) (312.24 KB - PDF)

Rodyti

español (ES) (232.03 KB - PDF)

Rodyti

čeština (CS) (307.25 KB - PDF)

Rodyti

dansk (DA) (233.01 KB - PDF)

Rodyti

Deutsch (DE) (235.26 KB - PDF)

Rodyti

eesti (ET) (231.11 KB - PDF)

Rodyti

ελληνικά (EL) (308.87 KB - PDF)

Rodyti

français (FR) (231.59 KB - PDF)

Rodyti

italiano (IT) (231.31 KB - PDF)

Rodyti

latviešu (LV) (309.08 KB - PDF)

Rodyti

lietuvių (LT) (262.26 KB - PDF)

Rodyti

magyar (HU) (304.77 KB - PDF)

Rodyti

Malti (MT) (309.64 KB - PDF)

Rodyti

Nederlands (NL) (234.5 KB - PDF)

Rodyti

polski (PL) (274.42 KB - PDF)

Rodyti

português (PT) (231.94 KB - PDF)

Rodyti

română (RO) (295.75 KB - PDF)

Rodyti

slovenčina (SK) (306.51 KB - PDF)

Rodyti

slovenščina (SL) (304.86 KB - PDF)

Rodyti

suomi (FI) (231.26 KB - PDF)

Rodyti

svenska (SV) (231.79 KB - PDF)

Rodyti

Product details

Name of medicine
Yarvitan
Active substance
mitratapide
International non-proprietary name (INN) or common name
mitratapide
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) code
QA08AB90

Pharmacotherapeutic group

Antiobesity preparations, excl. diet products

Therapeutic indication

As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight management programme which also includes appropriate dietary changes. Introducing appropriate lifestyle changes (e.g. increased exercise), in conjunction with this weight management programme, may provide additional benefits.

Authorisation details

EMA product number
EMEA/V/C/000113
Marketing authorisation holder
Janssen Pharmaceutica N.V.

Turnhoutseweg 30
B-2340 Beerse
Belgium

Marketing authorisation issued
14/11/2006
Revision
3

Assessment history

This page was last updated on

Share this page